

to: Food, water, appropriate hiking footwear, and sunscreen. There are no restrooms available.

Agenda items for the September 24, 2021, session include a recap and discussion of the previous day's field tour; an update from the Designated Federal Official; discussion of the Bridge Creek Area Allotment Management Plan and Environmental Impact Statement; information sharing about the Alvord Allotment Management Plan Environmental Assessment; and, an opportunity for Subcommittee members to share information from their constituents and present research. Any other matters that may reasonably come before the Subcommittee may also be included.

A public comment period is available on September 24 at 11:45 a.m. Depending on the number of people wishing to comment and the time available, the amount of time for oral comments may be limited. Sessions may end early if all business items are accomplished ahead of schedule or may be extended if discussions warrant more time. All meetings, including field tour sessions, are open to the public in their entirety.

Public Disclosure of Comments: Before including your address, phone number, email address, or other personal identifying information in your comments, please be aware that your entire comment—including your personal identifying information—may be made publicly available at any time. While you can ask us in your comment to withhold your personal identifying information from public review, we cannot guarantee that we will be able to do so.

(Authority: 43 CFR 1784.4–2)

Jeffrey Rose,

District Manager.

[FR Doc. 2021–17508 Filed 8–13–21; 8:45 am]

BILLING CODE 4310–33–P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Cooperative Research Group on HEDGE V

Notice is hereby given that, on June 22, 2021, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Cooperative Research Group on HEDGE V (“HEDGE V”) has filed written notifications simultaneously with the Attorney

General and the Federal Trade Commission disclosing (1) the identities of the parties to the venture and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.

Pursuant to Section 6(b) of the Act, the identities of the parties to the venture are: Cummins, Inc., Columbus, IN; Convergent Science, Madison, WI; GM Global Technology Operations, LLC (GMGTO), Detroit, MI; Volkswagen Aktiengesellschaft, Wolfsburg, GERMANY; and Robert Bosch LLC, Farmington Hills, MI. The general area of HEDGE V's planned activity is to identify ICE technologies to achieve 50% brake thermal efficiency while maintaining a stoichiometric air/fuel ratio suitable for three-way catalyst operation. Other topics of interest to the consortium include: large-bore s.i. combustion systems; assisted pre-chambers; Hybrid-ICE focus including ICE design for hybrid application; engine geometry changes; advanced combustion modes, SACI & D–EGR, sCO₂ as a cooling medium or WHR system; high-power and voltage systems including microwave enhanced heating, CO₂ Separation Membrane for Octane-on-Demand, and on-board hydrogen generation for combustion enhancement.

Suzanne Morris,

Chief, Premerger and Division Statistics, Antitrust Division.

[FR Doc. 2021–17509 Filed 8–13–21; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to The National Cooperative Research and Production Act of 1993—Medical CBRN Defense Consortium

Notice is hereby given that, on July 1, 2021, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Medical CBRN Defense Consortium (“MCDC”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, American Type Culture Collection,

Manassas, VA; Bugworks Research, Inc., Fremont, CA; and Indiana University, Bloomington, IN; Jubilant HollisterStier, Spokane, WA; Lumen Bioscience, Inc., Seattle, WA; MBio Diagnostics, Inc. dba LightDeck Diagnostics, Boulder, CO; UES, Inc., Dayton, OH; Vaxess Technologies, Inc., Cambridge, MA; Vector RX LLC, Elkridge, MD and VitriVax, Inc., Boulder, CO have been added as parties to this venture.

Also, Kestrel Corporation, Albuquerque, NM, has withdrawn as a party to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and MCDC intends to file additional written notifications disclosing all changes in membership.

On November 13, 2015, MCDC filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on January 6, 2016 (81 FR 513).

The last notification was filed with the Department on March 29, 2021. A notice was published in the **Federal Register** pursuant to Section 6(b) of the Act on April 20, 2021 (86 FR 20521).

Suzanne Morris,

Chief, Premerger and Division Statistics, Antitrust Division.

[FR Doc. 2021–17504 Filed 8–13–21; 8:45 am]

BILLING CODE 4410–11–P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Pistoia Alliance, Inc.

Notice is hereby given that, on June 23, 2021, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. Section 4301 *et seq.* (the “Act”), Pistoia Alliance, Inc. filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Scitara Corporation, Marlboro, MA; QunaSys, Bunkyo, JAPAN; Procter & Gamble, Mason, OH; PHEMI Systems Corp., Vancouver, CANADA; Orbis Labsystems Services, Leopardstown, IRELAND; Nutanix,